VANCOUVER, BC, Aug. 17,
2021 /CNW/ - Rakovina Therapeutics Inc. (TSXV: RKV)
("the Company"), a biopharmaceutical company committed to advancing
new cancer therapies based on novel DNA-damage response
technologies, is pleased to announce that its abstract entitled
In Vitro Activity and Efficacy of Novel Dual PARP-HDAC
Inhibitors has been accepted for presentation at the upcoming joint
meeting of the 2021 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics.
Hosted by the American Association for Cancer Research (AACR),
the National Cancer Institute (NCI), and the European Organisation
for Research and Treatment of Cancer (EORTC), the 2021 Molecular
Targets and Cancer Therapeutics conference will take place as a
virtual event October 7-10, 2021. The
conference has historically attracted academics, scientists, and
pharmaceutical industry representatives from across the globe to
discuss innovations in drug development, target selection, the
impact of new discoveries in cellular and molecular biology, and
early clinical trials.
"We look forward to presenting our work in developing precision
medicines that selectively target and kill tumor cells at this
prestigious meeting," said Prof. Mads
Daugaard, Rakovina Therapeutics' president and chief
scientific officer. "The meeting will represent the first
opportunity to highlight promising new data being developed around
our novel kt-3000 series of dual PARP-HDAC inhibitors as potential
new therapies against treatment-resistant cancers."
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new
cancer treatments based on novel DNA-damage response technologies.
The Company has established a pipeline of DNA-damage response
inhibitors with the goal of advancing one or more drug candidates
into human clinical trials and obtaining marketing approval for new
cancer therapeutics from Health Canada, the United States Food and
Drug Administration and similar international regulatory
agencies. Further information may be found at
www.rakovinatherapeutics.com.
Additional Information
The TSXV has neither approved nor disapproved the content of
this press release. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this
release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
the Company and its respective business, which may include, but is
not limited to, statements with respect to the proposed business
plan of the Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events, or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors, the equity markets generally and risks associated with
growth and competition. Although the Company has attempted
to identify important factors that could cause actual actions,
events, or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events, or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise. The
reader is referred to the Company's most recent filings on SEDAR
for a more complete discussion of all applicable risk factors and
their potential effects, copies of which may be accessed through
the Company's profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.